Trials / Completed
CompletedNCT01556997
Perindopril Amlodipine for the Treatment of Hypertension
Perindopril Amlodipine for the Treatment of Hypertension (PATH): A Multicenter, Randomized, Double-Blind, Parallel-Group Study Evaluating the Efficacy and Safety of a Fixed-Dose Combination of Perindopril Arginine Plus Amlodipine Besylate Versus Perindopril Erbumine and Amlodipine Besylate in Subjects With Essential Hypertension
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 837 (actual)
- Sponsor
- Symplmed Pharmaceuticals LLC · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the safety and efficacy of a fixed-dose combination drug compared to two other drugs (monotherapies) in controlling hypertension.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | XOMA 985 | PERa/AMLb capsule taken once daily by mouth for six weeks |
| DRUG | Amlodipine Besylate | AMLb capsule taken once daily by mouth for six weeks |
| DRUG | Perindopril Erbumine | PERe capsule taken once daily by mouth for six weeks |
Timeline
- Start date
- 2012-02-01
- Primary completion
- 2013-02-01
- Completion
- 2013-02-01
- First posted
- 2012-03-19
- Last updated
- 2015-09-28
- Results posted
- 2015-08-25
Locations
48 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01556997. Inclusion in this directory is not an endorsement.